Quotient Bioresearch has today announced its adoption of Bruker's MALDI Biotyper for bacterial identification, following a successful year-long trial.

The announcement, made at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) where Quotient  presented a series of posters, places the company in a unique position as the first GLP laboratory to adopt the technology for routine bacterial identification as part of its portfolio of services for antimicrobial development.

Dr Ian Morrissey, Director of Microbiology at Quotient, commented: "Quotient's expert Bioanalytical Sciences team is a fusion of microbiology, immunochemistry and mass-spectrometry specialists, which means we are perfectly placed to embrace this technology."

Delivering rapid and precise identification, Bruker's MALDI Biotyper technology enables Quotient to identify many thousands of organisms a year for antibiotic resistance surveillance, in a much more efficient and accurate manner than traditional identification methods.

Craig Parker, Global Market Manager for Microbiology at Bruker Daltonics, said: "It's great to see Quotient embracing our MALDI Biotyper technology and encompassing it within its own technical work."

Ian added: "The trial period of Bruker's MALDI Biotyper has proved very successful and we are confident that this technology represents the future of bacterial identification, and Quotient is proud to be at the forefront of this exciting field."

Quotient will be presenting two posters on MALDI-TOF technology at ICAAC.

‘D-1285 - Large Scale Performance Evaluation of MALDI-TOF MS in a Central Reference Laboratory Setting' is the largest industry study into MALDI-TOF and ‘D-1284 - Rapid Identification of Veterinary Enterococci by MALDI-TOF MS' analyses how MALDI-TOF technology can aid better identification of bacteria over traditional industry methods.

For further information, or to arrange a meeting, visit the website at www.quotientbioresearch.com/bioanalytical-sciences or email info@quotientbioresearch.com.